Totally agree, Pestell butted heads with Nader and sued over Nader firing him. the end result is Pestall gets his shares that we paid for in dilution and go no Oncology progress until he was fired. We also paid for his prostrate test that was sold to us as a turn key ready to generate revenue product but in reality still needed FDA trials and much work. We paid for that too. What a huge expensive distraction. I was on the side of Nader for firing him and pissed that we bought into his hype. This BOD owes ups a huge explanation for this - totally not in shareholders best interest.